Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
August 07 2020 - 4:05PM
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced
today that it has completed its previously announced offering of
$450 million in aggregate principal amount of its 3.875% Senior
Unsecured Notes due 2028 (the “Notes”).
The Notes are fully and unconditionally guaranteed on a senior
unsecured basis by all of the Company’s direct and indirect
subsidiaries that guarantee debt under its credit facilities. The
Company has used the net proceeds of the offering to repay the $353
million outstanding under its $600 million revolving credit
facility with the remainder to be used for general corporate
purposes.
The Notes were offered in the United States to qualified
institutional buyers pursuant to Rule 144A under the Securities Act
of 1933, as amended (the “Securities Act”), and outside the United
States pursuant to Regulation S under the Securities Act. The Notes
were not registered under the Securities Act and may not be offered
or sold in the United States except pursuant to an exemption from
the registration requirements of the Securities Act and applicable
state securities laws.
This press release is neither an offer to sell nor the
solicitation of an offer to buy the Notes or any other securities,
and there shall not be any offer to sell, solicitation of an offer
to buy or sale of the Notes in any jurisdiction in which, or to any
person to whom, such an offer, solicitation or sale is unlawful.
Any offers of the Notes will be made only by means of an offering
memorandum.
About Emergent BioSolutionsEmergent
BioSolutions is a global life sciences company whose mission is to
protect and enhance life. Through our specialty products and
contract development and manufacturing services, we are dedicated
to providing solutions that address public health threats. Through
social responsibility, we aim to build healthier and safer
communities. We aspire to deliver peace of mind to our patients and
customers so they can focus on what’s most important in their
lives. In working together, we envision protecting or enhancing 1
billion lives by 2030.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including statements
regarding the intended use of proceeds, are forward-looking
statements. We generally identify forward-looking statements by
using words like "will," "believes," "expects," "anticipates,"
"intends," "plans," "forecasts," "estimates" and similar
expressions. These forward-looking statements are based on our
current intentions, beliefs and expectations regarding future
events. We cannot guarantee that any forward-looking statement will
be accurate. Investors should realize that if underlying
assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our
expectations. Investors are, therefore, cautioned not to place
undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to
update any forward-looking statement to reflect new information,
events or circumstances.
There are a number of important factors that could cause our
actual results to differ materially from those indicated by such
forward-looking statements. In addition, new factors that could
cause actual results to differ from our expectations emerge from
time to time and it is not possible for management to predict all
such factors, nor can it assess the impact of any such factor on
the business or the extent to which any factor, or combination of
factors, may cause results to differ materially from those
contained in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in our periodic reports filed with the Securities and
Exchange Commission when evaluating our forward-looking
statements.
Investor Contact:Robert G. BurrowsVice
President, Investor Relations240-631-3280BurrowsR@ebsi.com
Media Contact:Miko B. NeriSenior Director,
Global Communications & Public
Affairs240-631-3392NeriM@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Sep 2023 to Sep 2024